The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Slayback Pharma LLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Azurity Pharmaceuticals, a pharmaceutical company specializing in the provision of innovative medicines to overlooked patients, on the acquisition of Slayback Pharma LLC ("Slayback"), a company focused on complex generic and specialty pharmaceutical products
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
GI Alliance
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
Acacia Pharma Group plc
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
US Acute Care Solutions
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Akorn, Inc.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Concordia International Corp.
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
![USA/Canada U.S.A., Canada flags](https://www.greenhill.com/sites/default/files/usa_canada.gif)
Concordia International Corp
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
![USA/UK U.S.A., U.K. flags](https://www.greenhill.com/sites/default/files/usa_uk.gif)
US rights to Toprol-XL (AstraZeneca)
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Recepta Biopharma
![Brazil Brazil flag](https://www.greenhill.com/sites/default/files/brazil.gif)
Advised Recepta Biopharma on a capital raise
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
American Dental Partners, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised American Dental Partners, Inc. (NASD: ADPI), one of the nation’s leading business partners to dental group practices, on its sale to JLL Partners, a leading private equity firm
![USA/Switzerland U.S.A., Swiss flags](https://www.greenhill.com/sites/default/files/usa_swiss.gif)
Alcon, Inc.
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Cardinal Health, Inc., Pharmaceutical Technologies and Services division
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Provided fairness opinion to the board of directors of Cardinal Health, Inc., a global company serving the health-care industry, on the sale of its Pharmaceutical Technologies and Services business, which provides outsourced services and proprietary technologies to the global pharmaceutical and biotechnology industries